Attached files
file | filename |
---|---|
EX-31.1 - EX-31.1 - VALEANT PHARMACEUTICALS INTERNATIONAL | a55268exv31w1.htm |
EX-31.2 - EX-31.2 - VALEANT PHARMACEUTICALS INTERNATIONAL | a55268exv31w2.htm |
EX-23 - EX-23 - VALEANT PHARMACEUTICALS INTERNATIONAL | a55268exv23.htm |
EX-3.3 - EX-3.3 - VALEANT PHARMACEUTICALS INTERNATIONAL | a55268exv3w3.htm |
EX-21 - EX-21 - VALEANT PHARMACEUTICALS INTERNATIONAL | a55268exv21.htm |
10-K - FORM 10-K - VALEANT PHARMACEUTICALS INTERNATIONAL | a55268e10vk.htm |
Exhibit 32
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on
Form 10-K
of Valeant Pharmaceuticals International (the
Company) for the period ended December 31, 2009
as filed with the Securities and Exchange Commission on the date
hereof (the Report), J. Michael Pearson, Chief
Executive Officer of the Company, and Peter J. Blott, Chief
Financial Officer of the Company, each certify pursuant to
18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 that:
1. The Report fully complies with the requirements of
Section 13(a) or Section 15(d) of the Securities
Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents,
in all material respects, the financial condition and results of
operations of the Company.
/s/ J. Michael
PearsonJ.
Michael Pearson Chairman and Chief Executive Officer |
/s/ Peter J.
BlottPeter
J. Blott Executive Vice President and Chief Financial Officer |
Date: February 23, 2010
This certification accompanies the
Form 10-K
to which it relates, is not deemed filed with the Securities and
Exchange Commission and is not to be incorporated by reference
into any filing of Valeant Pharmaceuticals International under
the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, as amended (whether made before or after
the date of the
Form 10-K),
irrespective of any general incorporation language contained in
such filing.